OMEROS CORP Cash and Restricted Cash
OMEROS CORP (OMER) had Cash and Restricted Cash of $6.60 million as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2023-08-09
- 2023-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.60M.
- 2023-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.83M.
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.01M.
- 2022-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $145.53M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2023-06-30 | $6.60M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $3.83M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.01M 10-Q · filed 2023-08-09 |
| 2022-09-30 | $145.53M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $14.14M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $8.96M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $100.81M 10-Q · filed 2023-08-09 |
| 2021-09-30 | $7.42M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $12.70M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $9.03M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $10.50M 10-K · filed 2023-03-13 |
| 2020-09-30 | $21.07M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $1.96M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $7.12M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $3.08M 10-K · filed 2023-03-13 |
| 2019-09-30 | $8.86M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $3.99M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $4.05M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $5.86M 10-K · filed 2022-03-01 |
| 2018-09-30 | $2.79M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $2.88M 10-Q · filed 2019-08-08 |
| 2017-12-31 | $3.39M 10-K · filed 2021-03-01 |
| 2016-12-31 | $2.22M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |